<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624710</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54707-105</org_study_id>
    <nct_id>NCT05624710</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, parallel-group study to evaluate INCB054707 in&#xD;
      participants with varying levels of renal function or impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 26, 2023</start_date>
  <completion_date type="Anticipated">November 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter: Cmax of INCBC054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as maximum observed plasma concentration of INCB054707</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter: AUC(0-t) of INCB054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as the area under the concentration- time curve up to the last measurable concentration of INCB54707.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Parameter: AUC(0-∞) of INCB054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as area under the concentration-time curve From 0 to Infinity of INCB054707</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE'S)</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: tmax of INCB054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as time to reach maximum plasma concentration of INCB054707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: t1/2 0f INCB054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as apparent terminal phase disposition half-life of INCB54707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter: CL/F of INCB054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as oral dose clearance of INCB054707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter:: Vz/F of INCB054707</measure>
    <time_frame>Days 1 - 5</time_frame>
    <description>Defined as apparent oral dose volume of distribution of INCB054707</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Insufficiency</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1: Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment (Class C Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (Class B Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment (Class A Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function will receive a single oral dose of INCB054707 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054707</intervention_name>
    <description>INCB054707 75 mg will be administered orally on Day 1.</description>
    <arm_group_label>Group 1: Severe Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 2: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 3: Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Group D: Normal Hepatic Function</arm_group_label>
    <other_name>Povorcitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Participants with hepatic impairment will be classified at screening based on Child-Pugh&#xD;
        score. Classification will be repeated at check-in and should not be significantly&#xD;
        different.&#xD;
&#xD;
        If the hepatic function classification for the participant is not similar at the 2&#xD;
        timepoints, enrollment of the participant into a hepatic category group will be at the&#xD;
        discretion of the investigator, in consultation with the sponsor's medical monitor. The&#xD;
        enrollment group will be based on the results at screening.&#xD;
&#xD;
          -  Participants eligible for Group 4 (normal hepatic function) should be in good health&#xD;
             as determined by no clinically significant findings in the medical history, physical&#xD;
             examination, vital signs, 12-lead ECGs, or laboratory examinations at screening or&#xD;
             check-in.&#xD;
&#xD;
          -  Participants eligible for Groups 1 through 3 may have medical findings consistent with&#xD;
             their degree of hepatic dysfunction, as determined by medical history, physical&#xD;
             examination, vital signs, 12-lead ECGs, and clinical laboratory examinations at&#xD;
             screening and check-in. Participants with abnormal findings considered not clinically&#xD;
             significant by the investigator are eligible.&#xD;
&#xD;
          -  BMI within the range of 18.0 to 44.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the opinion of the principal investigator, history of uncontrolled or unstable&#xD;
             cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or&#xD;
             neurological disease within 6 months of screening or evidence of rapidly deteriorating&#xD;
             hepatic function.&#xD;
&#xD;
          -  Serum corrected calcium and phosphorus levels over the upper limits of the&#xD;
             institutional normal ranges.&#xD;
&#xD;
          -  History or current diagnosis of uncontrolled or significant cardiac disease indicating&#xD;
             significant risk of safety for participation in the study, including any of the&#xD;
             following:&#xD;
&#xD;
               1. Recent myocardial infarction (within 6 months of check-in).&#xD;
&#xD;
               2. New York Heart Association Class III or IV congestive heart failure.&#xD;
&#xD;
               3. Unstable angina (within 6 months of check-in).&#xD;
&#xD;
               4. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained&#xD;
                  ventricular tachycardia, second or third degree atrioventricular block without a&#xD;
                  pacemaker).&#xD;
&#xD;
               5. Uncontrolled hypertension.&#xD;
&#xD;
          -  A current, functioning organ transplant or a scheduled organ transplant in the next 6&#xD;
             weeks from check-in.&#xD;
&#xD;
          -  History of malignancy within 5 years of screening, with the exception of cured basal&#xD;
             cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or&#xD;
             Gleason 6 prostate cancer.&#xD;
&#xD;
          -  History of clinically significant GI disease or surgery (cholecystectomy and&#xD;
             appendectomy are allowed) that could impact the absorption of study drug.&#xD;
&#xD;
          -  Severe ascites (ascites requiring paracentesis more than every 4 weeks) or an&#xD;
             encephalopathy ≥ Grade 2 (precludes them from understanding and signing an informed&#xD;
             consent).&#xD;
&#xD;
          -  Any major surgery within 4 weeks of screening.&#xD;
&#xD;
          -  Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for&#xD;
             plasma only).&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of check-in.&#xD;
&#xD;
          -  Current or recent history (within 30 days before screening) of a clinically&#xD;
             significant bacterial, fungal, parasitic, or mycobacterial infection, or currently&#xD;
             receiving systemic antibiotics or current clinically significant viral infection at&#xD;
             screening or check-in.&#xD;
&#xD;
          -  Positive serology for HBV (eg, HBsAg) or HIV. Participants whose results are&#xD;
             compatible with immunity due to infection or prior immunization for HBV may be&#xD;
             included at the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apex Gmbh</name>
      <address>
        <city>Munich</city>
        <zip>D-81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal impairment</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>Kidney failure</keyword>
  <keyword>end-stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

